Search Result

Results for "

IgG4κ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1) ADC Antibody (4) Apoptosis (3) c-Met/HGFR (2) C-type Lectin-like Receptors (CTLRs) (1) CD22 (2) CD28 (5) CD3 (3) CD47 (1) CD73 (1) CXCR (3) EGFR (1) ERK (1) Factor Xa (2) Fc Receptor (FcR) (1) Ferroportin (1) Hepcidin (1) IFNAR (2) IGF-1R (1) Integrin (1) Interleukin Related (15) JAK (1) LAG-3 (5) LILRB (1) MMP (1) Mucin (1) Neuropeptide Y Receptor (1) Orexin Receptor (OX Receptor) (2) PACAP Receptor (1) PAI-1 (1) PCSK9 (1) PD-1/PD-L1 (9) PDGFR (1) Prion Protein (1) PSMA (1) RANKL/RANK (1) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) TGF-β Receptor (1) Thrombin (1) TNF Receptor (6) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (10) VEGFR (2)
By Research Areas:	Cancer (24) Cardiovascular Disease (5) Inflammation/Immunology (72) Neurological Disease (2)

By Targets:

Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1)

ADC Antibody (4)

Apoptosis (3)

c-Met/HGFR (2)

C-type Lectin-like Receptors (CTLRs) (1)

CD22 (2)

CD28 (5)

CD3 (3)

CD47 (1)

CD73 (1)

CXCR (3)

EGFR (1)

ERK (1)

Factor Xa (2)

Fc Receptor (FcR) (1)

Ferroportin (1)

Hepcidin (1)

IFNAR (2)

IGF-1R (1)

Integrin (1)

Interleukin Related (15)

JAK (1)

LAG-3 (5)

LILRB (1)

MMP (1)

Mucin (1)

Neuropeptide Y Receptor (1)

Orexin Receptor (OX Receptor) (2)

PACAP Receptor (1)

PAI-1 (1)

PCSK9 (1)

PD-1/PD-L1 (9)

PDGFR (1)

Prion Protein (1)

PSMA (1)

RANKL/RANK (1)

Ser/Thr Protease (2)

Small Interfering RNA (siRNA) (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Thrombin (1)

TNF Receptor (6)

Toll-like Receptor (TLR) (1)

Transmembrane Glycoprotein (10)

VEGFR (2)

By Research Areas:

Cancer (24)

Cardiovascular Disease (5)

Inflammation/Immunology (72)

Neurological Disease (2)

Inhibitors & Agonists

106

Inhibitory Antibodies

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4].

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

Zigakibart BION-1301	TNF Receptor
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

Anti-VEGFB Antibody (CSL346) CSL346; Reflocibart	VEGFR	Inflammation/Immunology
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Anti-IL11RA Antibody (X209) EnX209	Interleukin Related ERK MMP	Inflammation/Immunology
Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a K_D of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human IgG4-kappa, anti-MET bispecific antibody. Davutamig binds 2 distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. Davutamig is applicable to the research of advanced non-small cell lung cancer with MET gene abnormalities .

Anti-PACAP38 Antibody	PACAP Receptor	Inflammation/Immunology
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

REGN-7257	Interleukin Related	Inflammation/Immunology
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

Torudokimab	Interleukin Related	Inflammation/Immunology
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4]. x

Nebaprubart JJP-1212	Fc Receptor (FcR)	Inflammation/Immunology
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .

Liscastobart BAT-1308	PD-1/PD-L1	Cancer
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

Zadoprubart	CD28	Inflammation/Immunology
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Dalmitamig bsAb7075; REGN-7075; Marlotamig	EGFR	Inflammation/Immunology
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Eltrekibart LY-3041658	CXCR	Inflammation/Immunology
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Venanprubart LY-3361237	CD28	Inflammation/Immunology
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Abiprubart KPL-404	TNF Receptor	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Indatuximab	Transmembrane Glycoprotein	Inflammation/Immunology
Indatuximab is a CHO-expressed chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 145.5 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

IMP-761	LAG-3	Cancer
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

Mibavademab	Neuropeptide Y Receptor	Inflammation/Immunology
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Anti-PVRIG Antibody (COM701) COM701	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

BI-765063 OSE-172	CD47	Inflammation/Immunology
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Anti-Hepcidin/HAMP Antibody (LY2787106)	Others Hepcidin Ser/Thr Protease	Inflammation/Immunology
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed human antibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).

Ponumkibart	Interleukin Related	Inflammation/Immunology
Ponumkibart is a humanized IgG4κ antibody targeting IL-17RB. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

Ticalicibart	PCSK9	Cardiovascular Disease
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .

Nelmastobart HSTC-810	Transmembrane Glycoprotein	Inflammation/Immunology
Nelmastobart is an anti-BTN1A1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Olsutamig REGN-4336	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

MDX-1105 BMS-936559	PD-1/PD-L1	Inflammation/Immunology
MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Anti-GREM1/Gremlin Antibody	TGF-beta/Smad	Inflammation/Immunology
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

Gimvekibart	Interleukin Related	Inflammation/Immunology
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting *IL-4Ra/CD124*. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .

Camtarkibart	Interleukin Related	Inflammation/Immunology
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Birinkibart	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Negalstobart IBI-110	LAG-3	Inflammation/Immunology
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Vilamakitug XB-2001	Interleukin Related	Inflammation/Immunology
Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Ichorcumab JNJ-375; JNJ-64179375; JNJ-9375	Thrombin	Cardiovascular Disease
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .

Iparomlimab	PD-1/PD-L1	Cancer
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Nadecnemab	TGF-β Receptor	Inflammation/Immunology
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .

Ubletamig	Mucin	Others
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99003

*Human IgG4* (S228P) kappa, Isotype Control** 5+ Cited Publications	Inhibitory Antibodies	Inflammation/Immunology
Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4].

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99299

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P990070

Zigakibart BION-1301	TNF Receptor
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P990540

Anti-VEGFB Antibody (CSL346) CSL346; Reflocibart	VEGFR	Inflammation/Immunology
Anti-VEGFB Antibody (CSL346) is a CHO-expressed human antibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human IgG4-kappa, anti-MET bispecific antibody. Davutamig binds 2 distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. Davutamig is applicable to the research of advanced non-small cell lung cancer with MET gene abnormalities .

HY-P990481

Anti-PACAP38 Antibody	PACAP Receptor	Inflammation/Immunology
Anti-PACAP38 Antibody is a human antibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991201

REGN-7257	Interleukin Related	Inflammation/Immunology
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990669

Torudokimab	Interleukin Related	Inflammation/Immunology
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4]. x

HY-P990770

Ucenprubart	Inhibitory Antibodies	Inflammation/Immunology
Ucenprubart is an anti-CD200R1 human IgG4κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991705

Nebaprubart JJP-1212	Fc Receptor (FcR)	Inflammation/Immunology
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991698

Liscastobart BAT-1308	PD-1/PD-L1	Cancer
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991038

Zadoprubart	CD28	Inflammation/Immunology
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990913

Dalmitamig bsAb7075; REGN-7075; Marlotamig	EGFR	Inflammation/Immunology
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990737

Eltrekibart LY-3041658	CXCR	Inflammation/Immunology
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990773

Venanprubart LY-3361237	CD28	Inflammation/Immunology
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990726

Abiprubart KPL-404	TNF Receptor	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990743

Gruticibart AB023; Xisomab 3G3; MAB 14E11	Inhibitory Antibodies	Inflammation/Immunology
Gruticibart is an anti-F11 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990607

Indatuximab	Transmembrane Glycoprotein	Inflammation/Immunology
Indatuximab is a CHO-expressed chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 145.5 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991301

IMP-761	LAG-3	Cancer
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P990631

Mibavademab	Neuropeptide Y Receptor	Inflammation/Immunology
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990496

Anti-PVRIG Antibody (COM701) COM701	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990670

TTX-030 Eltivutabart	Inhibitory Antibodies	Inflammation/Immunology
TTX-030 is a humanized antibody expressed in CHO cells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990555

BI-765063 OSE-172	CD47	Inflammation/Immunology
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990617

Anti-Hepcidin/HAMP Antibody (LY2787106)	Inhibitory Antibodies Hepcidin Ser/Thr Protease	Inflammation/Immunology
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed human antibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991710

Ponumkibart	Interleukin Related	Inflammation/Immunology
Ponumkibart is a humanized IgG4κ antibody targeting IL-17RB. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991721

Ticalicibart	PCSK9	Cardiovascular Disease
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .

HY-P990751

Nelmastobart HSTC-810	Transmembrane Glycoprotein	Inflammation/Immunology
Nelmastobart is an anti-BTN1A1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991708

Olsutamig REGN-4336	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

HY-P990623

MDX-1105 BMS-936559	PD-1/PD-L1	Inflammation/Immunology
MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990426

Anti-GREM1/Gremlin Antibody	TGF-beta/Smad	Inflammation/Immunology
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P99106

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

HY-P991688

Gimvekibart	Interleukin Related	Inflammation/Immunology
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting *IL-4Ra/CD124*. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .

HY-P991675

Camtarkibart	Interleukin Related	Inflammation/Immunology
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990975

Birinkibart	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990750

Negalstobart IBI-110	LAG-3	Inflammation/Immunology
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990691

Vilamakitug XB-2001	Interleukin Related	Inflammation/Immunology
Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991065

Ichorcumab JNJ-375; JNJ-64179375; JNJ-9375	Thrombin	Cardiovascular Disease
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P99668

Iparomlimab	PD-1/PD-L1	Cancer
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P990515

Anti-TCR Antibody (NKTT320) NKTT320	Inhibitory Antibodies	Inflammation/Immunology
Anti-TCR Antibody (NKTT320) is a humanized antibody expressed in CHO, targeting TCR. Anti-TCR Antibody (NKTT320) features huIgG4 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TCR Antibody (NKTT320) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990551

Atinumab (NG-101) NG-101	Inhibitory Antibodies	Inflammation/Immunology
Atinumab (NG-101) is a CHO-expressed human antibody that targets *RTN4/NOGO. Atinumab (NG-101) carries a huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Atinumab (NG-101) can be referenced as Human IgG4 kappa*, Isotype Control (HY-P99003).

HY-P990384

Anti-CSF3R/G-CSFR Antibody	Inhibitory Antibodies	Inflammation/Immunology
Anti-CSF3R/G-CSFR Antibody is a CHO-expressed human antibody that targets CSF3R/G-CSFR. Anti-CSF3R/G-CSFR Antibody contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CSF3R/G-CSFR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990063

Mevonlerbart	Inhibitory Antibodies	Others
Mevonlerbart is an IgG4κ antibody targeting human Felcat allergen 1. Felcat allergen 1 is an allergen protein.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: